Lv1
40 积分 2021-06-12 加入
Fibrosing Skin Disorder Associated With Zilucoplan
23天前
已关闭
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
1个月前
已完结
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
3个月前
已完结
Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis
5个月前
已完结
Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg
5个月前
已完结
Double‐Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity‐Stratified Benefits in a Prospective Observational Multicenter Study
5个月前
已完结
The Fiscal Consequences for the Canadian Government of Efgartigimod in the Treatment of Generalized Myasthenia Gravis
5个月前
已关闭
Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study
5个月前
已完结
Safety and Effectiveness of Eculizumab in Patients With Refractory Ocular or Ocular‐Predominant Myasthenia Gravis: A Case Series
6个月前
已完结
Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report
6个月前
已完结
皖公网安备34019202002308
